Virinchi Limited (NSE: VIRINCHI | BSE: 526901)
Source: Virinchi Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026)
📋 Quick Facts: Company Snapshot
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Virinchi Limited |
| Corporate Identity Number (CIN) | L72200TG1990PLC011104 |
| Stock Exchange Listing | BSE Limited (526901) & National Stock Exchange of India Limited (VIRINCHI) |
| Date of Incorporation / Founding Year | 1990 (Operating since 1991) |
| Founders / Key Founding Figures | Viswanath Kompella (Founder & Chairman Emeritus) |
| Registered Office & Corporate Headquarters | 8-2-672/5&6, 4th Floor, Ilyas Mohammed Khan Estate, Road No. 1, Banjara Hills, Hyderabad – 500034, Telangana, India |
| Telephone & Official Investor Relations Email | 040-43728111 | investors@virinchi.com |
| Chairman / Managing Director & CEO | M.V. Srinivasa Rao (Chairman, Whole Time Director & CFO); Amar Sivaji Pendyala (CEO – US Business) |
| Chief Financial Officer (CFO) & Company Secretary (CS) | M.V. Srinivasa Rao (CFO); K. Ravindranath Tagore (Company Secretary & Compliance Officer) |
| Promoter & Holding Group | Viswanath Kompella and Promoter Group Entities |
| Total Employees / Workforce | 1,160 Total Resources across Group (IT: 460 resources; Healthcare: 700 resources; Standalone Permanent Rolls: 559) |
| Key Development Hubs & Hospital Facilities | Technology: Banjara Hills & Hakimpet (Hyderabad), Marlboro (New Jersey, USA), Santa Clara & Atlanta (Data Centres); Healthcare: Banjara Hills, Barkatpura, Hayathnagar (Hyderabad) |
| Credit Ratings & Rating Agency | Acuite BB+ (Stable) for Long-Term Bank Facilities; Acuite A4+ for Short-Term Bank Facilities (Rs. 25.00 Cr bank facilities) |
| Statutory Auditors | M/s. P. Murali & Co., Chartered Accountants (FRN: 007257S) |
| Secretarial Auditors | M/s. G. Vinay Babu, Practicing Company Secretary (CP No. 20707) |
| Registrar and Share Transfer Agent (RTA) | M/s. Aarthi Consultants Private Limited, 1-2-285, Domalguda, Hyderabad – 500029, Telangana |
🏢 The Corporate Identity: Virinchi Limited Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Virinchi Limited operates as an integrated enterprise straddling three high-growth industry pillars: Financial Technology Software-as-a-Service (Fintech SaaS), Internet Data Centres & Information Technology Services (IDC & IT Services), and Tertiary Healthcare Delivery. The overarching architecture of the business focuses on transforming technology into intelligent operational execution, transitioning from exploratory artificial intelligence toward production-grade workflows across credit assessment and healthcare interventions.
In the fintech technology domain, the company’s enterprise SaaS platform, QFund, manages the end-to-end loan lifecycle for alternative micro-lenders in North America, covering origination, real-time risk profiling, compliance checks, loan disbursement, and collections. In healthcare, the enterprise operates tertiary multi-specialty hospital infrastructure in Hyderabad, anchored by digital clinical mobility platforms, electronic medical record systems, and advanced diagnostic technologies.
- Convergence Architecture: Embedding predictive analytics, machine learning, and process automation across short-term alternative micro-lending and multi-specialty tertiary clinical care.
- Cloud-Hosted Delivery: Providing hosted multi-tenant and single-tenant enterprise financial infrastructure to top-tier North American storefront and online lenders.
- Integrated Digital Care: Deploying proprietary hospital information systems and clinical dashboards to deliver transparent, protocol-driven tertiary and quaternary medical treatments.
The Founders, Promoters & Their Legacy
Virinchi Limited was founded in 1990 by First Generation IIT/IIM entrepreneurs under the leadership of Viswanath Kompella, who currently serves as Founder & Chairman Emeritus. Under his strategic guidance, the enterprise diversified from software consulting into proprietary intellectual property creation, addressing the niche regulatory and underwriting challenges of North American alternative finance institutions before expanding into capital-intensive healthcare infrastructure.
The promoter group continues to play an active governance and capital allocation role. During FY 2025-26, the promoter family supported corporate restructuring and capital expansion through the direct infusion of equity and warrants into both Virinchi Limited and its healthcare operating subsidiary, Virinchi Health Care Private Limited, infusing ₹7.83 Crores into the subsidiary to obtain a 49% stake while leaving 51% with the listed parent.
The Journey: Corporate History & Key Milestones
Over a span of 35 years, Virinchi evolved through deliberate pivots that expanded its balance sheet and global operating footprint:
- 1990–1991: Incorporation of the company and launch of commercial operations focused on IT products, software engineering, and supply chain management applications.
- Early 2000s: Conceptualisation, proprietary development, and rollout of QFund, targeted at the non-banking retail alternative finance and short-term micro-credit market in the United States.
- 2006: Acquisition of U.S.-based IT consulting and services firm KSoft Systems Inc., establishing an onshore operational base in New Jersey and expanding co-located data centre facilities.
- 2012–2015: Strategic entry into healthcare delivery through investments in Bristlecone Hospitals and the subsequent acquisition of Asclepius Consulting & Technologies Private Limited to secure proprietary Hospital Information Management Systems (HIMS).
- 2016: Commissioning of the flagship 400-bed Virinchi Hospitals tertiary care facility at Banjara Hills, Hyderabad, constructed across a centrally located super mall under a 30-year lease.
- FY 2025-26: Execution of a ₹64.51 Crore convertible equity warrant issue to strengthen group capitalization, debt reduction, and healthcare restructuring. Subsequent to year-end, shareholders approved the acquisition of two hospital branches (Barkatpura and Hayathnagar) via a slump sale for ₹100.00 Crores.
The Corporate Umbrella & Group Structure
The corporate structure of Virinchi Limited encompasses domestic and international operating entities that segregate technology intellectual property, IT infrastructure, fintech lending, training, and healthcare delivery assets.
The primary revenue-generating subsidiaries are KSoft Systems Inc. (100% owned, incorporated in the USA for offshore/onshore IT consulting and data centres) and Virinchi Health Care Private Limited (51% held listed-parent equity, housing tertiary clinical healthcare delivery). Additional 100%-owned specialized entities include QFund Technologies Private Limited, Virinchi Capital Private Limited, Virinchi Learning Private Limited, and Asclepius Consulting & Technologies Private Limited (51% held).
⚙️ The Business Engine: Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Virinchi Limited organises its commercial operations into three primary reporting business segments, alongside secondary IT-enabled and fintech activities:
- SaaS Business (US Fintech – QFund): Proprietary software-as-a-service loan management platform for alternative financial institutions in North America.
- IDC & IT Services: Cloud hosting, co-located data centres, offshore/onshore software development, and specialized technical staffing managed via KSoft Systems Inc.
- Healthcare Services: Tertiary multi-specialty clinical operations, diagnostics, pharmacy dispensing, and surgical procedures managed via Virinchi Health Care Private Limited.
- IT Enabled Services: Back-office technology-driven support, e-governance vocational skill programs, and outsourced workflow operations.
| Segment Name | Segment Revenue (₹ Cr) FY 2025-26 | Segment Revenue (₹ Cr) FY 2024-25 | % Share of Total Revenue (FY26) | Segment Results / PBIT (₹ Cr) FY 2025-26 | Segment Results / PBIT (₹ Cr) FY 2024-25 | Latest YoY (%) |
|---|---|---|---|---|---|---|
| SaaS Business | 153.94 | 133.37 | 54.14% | 13.18 | 19.84 | +15.42% |
| IDC & IT Services | 40.37 | 57.30 | 14.20% | -2.37 | 18.59 | -29.55% |
| Healthcare Services | 79.99 | 104.15 | 28.13% | 0.15 | -0.88 | -23.20% |
| IT Enabled Services | 10.07 | 6.10 | 3.54% | 1.01 | -0.18 | +65.08% |
| Payments & Credit Services | 0.00 | 0.21 | 0.00% | -3.75 | -3.15 | -100.00% |
| Total Segment Operations | 284.36 | 301.13 | 100.00% | 8.21 | 34.23 | -5.57% |
Operating profitability diverged across operating divisions during the fiscal year. The SaaS business maintained robust volume expansion with a 15.42% increase in turnover, driven by revenue stabilization from newly onboarded tier-one alternative finance enterprises (Check-n-Go and MoneyTree Inc.). The IDC & IT Services division contracted by 29.55%, driven by tighter U.S. immigration restrictions on H-1B visas affecting onshore technical staffing deployments, resulting in a segment loss before interest and tax of ₹2.37 Crores.
Healthcare Services recorded an EBIT recovery to ₹0.15 Crores despite a 23.20% decrease in top-line receipts. This improvement was driven by a conscious strategic withdrawal from low-margin, extended-credit government health schemes in favor of high-acuity elective specialties, lifting healthcare EBITDA margins to 29.60% compared to 23.74% in FY 2024-25.
The Product & Service Catalog (with Operational KPIs & Order Book)
The enterprise delivers specialised product and service suites configured for North American alternative finance and Indian tertiary healthcare delivery:
- QFund Loan Management System: Comprehensive SaaS core software suite for storefront, online, mobile, text, and voice-assisted credit origination. Supports deferred presentment transactions, short-term installment facilities, title loans, and lines of credit with real-time fraud mitigation and payroll-deduction integrations.
- vCard Fintech Solution: Mobile-based digital credit line application designed in partnership with Indian regulated banking institutions to expand formal financial inclusion among underbanked domestic segments.
- IT Consulting & Cloud Managed Infrastructure: Full lifecycle enterprise solutions covering SAP, Oracle, mobile architecture, SMAC technologies, machine learning workflows, and hybrid hosting out of co-located facilities.
- Tertiary Clinical Care Infrastructure: Multi-specialty clinical treatments across 40+ medical specialties under the CONNECT vertical, including advanced cardiology, nephrology, robotic-assisted surgery, inter-state organ transplants, and regenerative cellular therapies.
The Names You Know: Key Brands & Flagship Portfolio
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| QFund | Fintech Enterprise SaaS | North American alternative lending institutions; omni-channel loan lifecycle management platform |
| Virinchi Hospitals | Tertiary Healthcare Delivery | Urban and regional Indian healthcare; technologically advanced tertiary and quaternary medical care |
| vCard | Digital Credit Inclusion Platform | Indian consumer fintech; mobile credit line enabling access for underbanked retail borrowers |
| vHealth | Healthcare IT / Proprietary EMR | Hospital clinical workflow; proprietary electronic medical records and executive analytics platform |
QFund holds a defensible niche footprint, currently serving five of the largest alternative finance organizations operating storefront and online lending networks across the United States. Virinchi Hospitals represents the flagship consumer-facing clinical brand in southern India, differentiated through high-density intensive care units, advanced radiodiagnostics, and specialized tertiary surgical procedures.
Mapping the Domestic & Global Reach (India vs. Exports)
Virinchi Limited maintains an export-oriented software profile paired with a domestically anchored healthcare delivery base.
| Geographic Market | Revenue (₹ Cr) FY 2025-26 | Revenue (₹ Cr) FY 2024-25 | % Share of Total Revenue (FY26) | Key Focus Areas & Deliverables | Latest YoY (%) |
|---|---|---|---|---|---|
| International / Export (United States) | 194.31 | 190.67 | 68.33% | QFund SaaS Platform subscriptions, hosted data services, enterprise IT consulting | +1.91% |
| Domestic (India) | 90.05 | 110.46 | 31.67% | Tertiary inpatient hospital care, outpatient consultations, pharmacy retail, domestic ITES | -18.48% |
| Total Operating Revenues | 284.36 | 301.13 | 100.00% | Consolidated operational footprint | -5.57% |
Export activities are concentrated in the United States, generating 68.33% of operational revenue in FY 2025-26 (up from 63.30% in FY 2024-25). International delivery is anchored by the company’s onshore base in Marlboro, New Jersey, and co-located Internet Data Centres in Atlanta and Santa Clara, controlled remotely from the Global Development Center in Hakimpet, Hyderabad.
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
The enterprise operates physical healthcare facilities and technology development centers across Telangana, India, and the United States:
- Banjara Hills Flagship Facility (Hyderabad): 400-bed multi-specialty tertiary care hospital operating under a 30-year lease agreement across 63 property owners. Houses 11 modular operation theatres, 130 ICU beds, 100 single patient rooms, a 3-Tesla functional MRI, 128-slice dual-energy CT, and ceiling-mounted IVUS Cathlab.
- Barkatpura & Hayathnagar Branches (Hyderabad): Secondary and tertiary hospital branches with combined operational capacity bringing group aggregate beds to 600 (scalable to 800 beds).
- Hakimpet Global Development Center (Hyderabad): Software engineering hub and remote control command facility situated at Survey No. 121, Pothaipally Village, Shamirpet, RR District, overseeing co-located US data centres.
- Banjara Hills Corporate Technology Hub (Hyderabad): Software development center and registered corporate headquarters located at Ilyas Mohammed Khan Estate.
- Marlboro Onshore Center (New Jersey, USA): U.S. headquarters for KSoft Systems Inc., located at Green House, 7 South Main Street, Suite E.
- Santa Clara & Atlanta Data Centres (USA): Co-located, carrier-grade internet data centre infrastructure powering QFund SaaS clients.
📊 The Financial Health: The Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
| Consolidated Financial Metric | FY 2025-26 | FY 2024-25 | FY 2023-24 | Latest YoY (%) |
|---|---|---|---|---|
| Total Income | 286.13 | 308.30 | 304.83 | -7.19% |
| Revenue from Operations | 284.36 | 301.13 | — | -5.57% |
| EBITDA (Profit before Interest, Depr, Tax & Except.) | 71.50 | 96.39 | 113.88 | -25.82% |
| EBITDA Margin (%) | 24.99% | 31.26% | 37.36% | – |
| Net Profit / (Loss) After Tax (PAT) | -26.12 | 0.72 | 13.48 | N/M |
| Debt-to-Equity Ratio (x) | 0.29x | 0.34x | 0.44x | -14.71% |
| Interest Coverage Ratio (x) | 2.17x | 2.47x | 2.65x | -12.15% |
| Total Equity / Net Worth | 482.16 | 474.27 | — | +1.66% |
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
| Statement of Profit and Loss Line Items | FY 2025-26 (₹ Cr) | FY 2024-25 (₹ Cr) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 284.36 | 301.13 | -5.57% |
| Other Income | 1.77 | 7.17 | -75.31% |
| Total Income | 286.13 | 308.30 | -7.19% |
| Expenses | |||
| Purchase of Stock in trade | 12.14 | 12.71 | -4.48% |
| Changes in Inventory | -2.48 | 1.56 | N/M |
| Employee Benefit Expenses | 101.89 | 96.80 | +5.26% |
| Depreciation | 55.40 | 54.73 | +1.22% |
| Amortization | 0.82 | 0.25 | +228.00% |
| Finance costs | 32.92 | 39.03 | -15.65% |
| Administrative and Other Operating Expenses | 103.08 | 100.86 | +2.20% |
| Total Expenses | 303.77 | 305.93 | -0.71% |
| Profit / (Loss) before Extraordinary Items and Tax | -17.64 | 2.37 | N/M |
| Less: Prior Period Items | 5.30 | 0.00 | N/M |
| Profit / (Loss) Before Tax | -22.93 | 2.37 | N/M |
| Tax expense – Current tax | 7.05 | 6.42 | +9.81% |
| Tax expense – Deferred tax | -2.59 | -4.54 | -42.95% |
| Profit / (Loss) for the Period | -26.12 | 0.72 | N/M |
| Profit attributable to Non Controlling Interest | -1.27 | -0.24 | +429.17% |
| Profit / (Loss) Attributable to Owners of the Company (PAT) | -26.12 | 0.72 | N/M |
Consolidated operations swung to a net loss of ₹26.12 Crores in FY 2025-26, compared to a profit of ₹0.72 Crores in the preceding fiscal year. Operating performance was impacted by three distinct factors: an administrative bad-debt write-off of ₹8.43 Crores on aged QC Holdings receivables, ₹5.30 Crores of prior-period tax adjustments, and persistent financing charges of ₹17.83 Crores arising from Ind AS 116 lease accounting liabilities for hospital facilities.
Standalone operations reported a contrasting profit after tax of ₹13.98 Crores (down 12.84% from ₹16.04 Crores), demonstrating the underlying earning power of the pure SaaS QFund software licensing engine when isolated from capital-intensive subsidiary healthcare charges.
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
| Consolidated Balance Sheet Line Items | As at 31 Mar 2026 (₹ Cr) | As at 31 Mar 2025 (₹ Cr) | Latest YoY (%) |
|---|---|---|---|
| ASSETS: Non-Current Assets | |||
| Property, Plant and Equipment | 308.80 | 337.83 | -8.59% |
| Right of Use Asset | 71.84 | 77.33 | -7.10% |
| Capital Work-In-Progress | 85.98 | 85.98 | 0.00% |
| Goodwill | 41.42 | 41.42 | 0.00% |
| Other Intangible Assets | 110.13 | 112.05 | -1.71% |
| Investments | 1.37 | 1.64 | -16.46% |
| Other Financial Assets | 4.85 | 5.20 | -6.73% |
| Other Non-Current Assets | 2.44 | 2.81 | -13.17% |
| Total Non Current Assets | 626.83 | 664.26 | -5.63% |
| Current Assets | |||
| Inventories | 7.82 | 5.33 | +46.72% |
| Trade Receivables | 86.85 | 81.19 | +6.97% |
| Cash and Cash Equivalents | 8.66 | 7.76 | +11.60% |
| Loans and ICD’s | 87.98 | 62.43 | +40.93% |
| Other Current Assets | 32.23 | 26.37 | +22.22% |
| Total Current Assets | 223.54 | 183.09 | +22.09% |
| TOTAL ASSETS | 850.37 | 847.35 | +0.36% |
| EQUITY AND LIABILITIES: Equity | |||
| Equity Share Capital | 108.80 | 102.65 | +5.99% |
| Other Equity | 383.82 | 373.20 | +2.85% |
| Non-Controlling Interest | -10.46 | -1.57 | +566.24% |
| Total Equity | 482.16 | 474.27 | +1.66% |
| Non-Current Liabilities | |||
| Non-Current Borrowings | 87.76 | 99.17 | -11.51% |
| Lease Liability | 132.06 | 132.50 | -0.33% |
| Other Non Current Liabilities | 7.15 | 6.49 | +10.17% |
| Deferred Tax Liabilities (Net) | 9.17 | 11.76 | -22.02% |
| Total Non-Current Liabilities | 236.13 | 249.92 | -5.52% |
| Current Liabilities | |||
| Current Borrowings | 53.56 | 60.82 | -11.94% |
| Trade Payables | 9.27 | 8.16 | +13.60% |
| Provisions | 69.25 | 54.17 | +27.84% |
| Total Current Liabilities | 132.08 | 123.15 | +7.25% |
| TOTAL LIABILITIES (Non-Current + Current) | 368.21 | 373.07 | -1.30% |
| TOTAL EQUITY AND LIABILITIES | 850.37 | 847.35 | +0.36% |
The consolidated balance sheet shows an improved financial gearing profile. Total debt (non-current borrowings of ₹87.76 Crores plus current borrowings of ₹53.56 Crores) stood at ₹141.32 Crores at year-end, down from ₹159.99 Crores in the previous year. This debt reduction, coupled with equity expansion via warrant conversions, lowered the group debt-to-equity ratio from 0.34x to 0.29x.
Working capital metrics shifted during the year, with debtor turnover days expanding from 98.42 days to 111.48 days. This elongation was driven by longer billing clearance timelines from institutional and scheme payers in healthcare, prompting management’s decision to write off non-recoverable receivables and pivot toward private-pay and commercial insurance clients.
Cash Flow: Tracking the Money Movement
| Consolidated Cash Flow Activities | FY 2025-26 (₹ Cr) | FY 2024-25 (₹ Cr) | Latest YoY (%) |
|---|---|---|---|
| Operating Profit before Working Capital Changes | 66.20 | 96.39 | -31.32% |
| Changes in Working Capital Assets & Liabilities | -33.11 | -1.81 | +1729.28% |
| Cash Generated from Operations | 33.09 | 94.58 | -65.01% |
| Direct Taxes & Working Capital Interest Paid | -12.10 | -10.60 | +14.15% |
| Net Cash Generated from Operating Activities | 20.99 | 83.98 | -75.01% |
| Purchase of Fixed Assets (CapEx) | 18.95 | 79.03 | -76.02% |
| Sale of Investments | 0.26 | 1.43 | -81.82% |
| Net Cash Used in Investing Activities | -18.69 | -77.59 | -75.91% |
| Proceeds from Equity Shares | 2.24% | 5.75% | – |
| Proceeds from / (Repayment of) Share Warrants | 2.24% | 5.75% | – |
| Interest and Finance Cost Paid | -25.27 | -30.31 | -16.63% |
| Net Repayment of Long-Term Borrowings | -11.41 | -8.33 | +36.97% |
| Change in Minority Interest | -8.88 | -0.24 | +3600.00% |
| Net Cash Used in Financing Activities | -1.40 | -18.65 | -92.49% |
| Net Increase / (Decrease) in Cash & Cash Equivalents | 0.90 | -12.27 | N/M |
| Cash and Cash Equivalents at Beginning of Year | 7.76 | 20.03 | -61.26% |
| Cash and Cash Equivalents at End of Year | 8.66 | 7.76 | +11.60% |
Funding the Future: CapEx, CWIP, R&D & Foreign Exchange
Consolidated capital expenditures during FY 2025-26 were focused on software enhancements and specialised medical technology. Intangible asset capitalization included ₹17.72 Crores allocated to internal product development, reflecting ongoing engineering enhancements to the QFund core lending engine and proprietary healthcare software.
Tangible property, plant, and equipment additions totaled ₹0.62 Crores, primarily comprising clinical medical hardware. Capital work-in-progress (CWIP) remained steady at ₹85.98 Crores, representing civil works and structural construction for the dedicated radiation oncology block and mother & child care wing at Banjara Hills, scheduled for phased commissioning by April 2028.
Under Section 134(3)(m) disclosures, the company generated ₹95.24 Crores in foreign exchange earnings through software exports and IT consulting services, up from ₹0.71 Crores in FY 2024-25. Total foreign exchange outgo stood at ₹0.20 Crores, compared to ₹0.26 Crores in the preceding year.
👥 Power & Control: Corporate Governance, Leadership & Ownership
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| M.V. Srinivasa Rao | Chairman, Whole Time Director & CFO | 00816334 | Executive Director (KMP) |
| V. Satyanarayana | Vice Chairman & Executive Director | 09070986 | Executive Director (Liable to retire by rotation) |
| K. Sri Kalyan | Non-Independent Non-Executive Director | 03137506 | Non-Executive Non-Independent |
| K. Kalpana | Independent Non-Executive Director | 07328517 | Non-Executive Independent (Audit Committee Chair) |
| T. Shyam Sunder | Independent Non-Executive Director | 07167885 | Non-Executive Independent |
| Priya Rajender Goda | Independent Non-Executive Director | 07402785 | Non-Executive Independent (Appointed June 11, 2025) |
| K. Ravindranath Tagore | Company Secretary & Compliance Officer | M.No: A18894 | Key Managerial Personnel (CS) |
Board committees maintain independent governance majorities across statutory functions. The Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee are each chaired by Independent Director Ms. K. Kalpana. Independent Director J. Suresh resigned from the board effective June 1, 2025, due to personal reasons, and Ms. Priya Rajender Goda was appointed as an Independent Director effective June 11, 2025.
Who Owns the Stock? Shareholding Pattern
As of March 31, 2026, the paid-up share capital of Virinchi Limited comprised 10,87,96,896 equity shares of face value ₹10 each, representing an aggregate equity base of ₹108.80 Crores.
| Shareholder Category | Number of Shares Held | % of Paid-Up Equity Capital |
|---|---|---|
| Promoters & Promoter Group | 4,36,25,538 | 40.10% |
| Public – Non-Institutional & Others | 6,51,71,358 | 59.90% |
| Total Equity Share Capital | 10,87,96,896 | 100.00% |
Promoter holdings increased from 3,85,05,538 equity shares to 4,36,25,538 shares during the fiscal year, primarily reflecting the conversion of 51,00,000 equity warrants by promoter-controlled entity Vivo Bio Tech Limited at ₹28 per share. Substantial individual and corporate equity holders include:
- Viswanath Kompella (Promoter): 1,63,70,888 shares (15.05% equity stake).
- Gajwel Developers Private Limited: 60,00,000 shares (5.52% equity stake).
- Vivo Bio Tech Limited (Promoter Entity): 51,00,000 shares (4.69% equity stake).
- Kompella Ramakrishna Paramahamsa: 43,41,250 shares (3.99% equity stake).
- Lopa Mudra Kompella: 40,21,250 shares (3.70% equity stake).
- PKI Solutions Private Limited: 39,30,990 shares (3.61% equity stake).
🗺️ The Corporate Family Tree: Group Structure & Strategic Investments
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
| Entity Name | Relationship | Country | % Shareholding | Turnover (₹ Cr) FY26 | Profit / (Loss) After Tax (₹ Cr) FY26 |
|---|---|---|---|---|---|
| KSoft Systems Inc. | Subsidiary | USA | 100% | 40.39 | -2.86 |
| QFund Technologies Private Limited | Subsidiary | India | 100% | 0.00 | -0.48 |
| Virinchi Learning Private Limited | Subsidiary | India | 100% | 0.03 | -0.12 |
| Virinchi Infra and Reality Private Limited | Subsidiary | India | 100% | 0.00 | -0.41 |
| Tyohar Foods Private Limited | Subsidiary | India | 100% | 0.03 | -0.69 |
| Virinchi Media & Entertainment Private Limited | Subsidiary | India | 100% | 0.00 | 0.00 |
| Virinchi Health Care Private Limited | Subsidiary | India | 51% | 83.32 | -33.26 |
| Asclepius Consulting & Technologies Private Limited | Subsidiary | India | 51% | 0.00 | -0.50 |
| Tensor Fields Consultancy Services Private Limited | Subsidiary | India | 100% | 0.00 | -0.11 |
| Virinchi Combinatorics & Systems Biology Private Limited | Subsidiary | India | 100% | 0.03 | -0.17 |
| V23 Medical Solutions Private Limited | Subsidiary | India | 100% | 0.13 | -0.02 |
| Virinchi Capital Private Limited | Subsidiary | India | 100% | 0.00 | -2.74 |
Virinchi Technologies Limited (Canada) remains incorporated but has not yet commenced commercial activities. During the reporting year, the parent company’s equity holding in Virinchi Health Care Private Limited diluted from 100% to 51% following the direct issuance of 52,22,000 equity shares to promoter Viswanath Kompella for ₹7.83 Crores.
Strategic Investments, Credit Facilities & Contingent Liabilities
Working capital and long-term debt facilities are secured by primary hypothecation over movable equipment, receivables, and commercial properties:
- Primary Working Capital Charges: First pari passu charge over movable fixed assets, inventories, and book debts in favour of ICICI Bank Limited for facilities availed by Virinchi Health Care Private Limited.
- Collateral Mortgages: Freehold corporate land admeasuring 875 sq. yards at Road No. 1, Banjara Hills, Hyderabad; commercial premises admeasuring 46,590 sq. ft. at Suraram, Jeedemetla; and factory land admeasuring 3 acres 36 guntas at Hakimpet mortgaged to ICICI Bank and Canara Bank.
- Promoter Personal Guarantees: Viswanath Kompella provides comprehensive personal guarantees across all bank debt facilities of the holding company and operating subsidiaries. Mrs. Madhavi Latha Kompella provides personal guarantees backing Virinchi Health Care Private Limited bank credit lines.
- Corporate Guarantees: Virinchi Limited maintains a corporate guarantee extended to ICICI Bank on behalf of Virinchi Health Care Private Limited for ₹39.84 Crores, with an outstanding credit exposure of ₹20.94 Crores as of March 31, 2026.
- Disputed Income Tax Contingencies: Pending statutory appellate claims include ₹2.69 Crores for AY 2017-18 before CIT(A) (₹0.40 Crores deposited), ₹4.52 Crores for AY 2021-22 before the High Court of Telangana, and ₹0.77 Crores for AY 2022-23 before the Income Tax Appellate Tribunal (ITAT), Hyderabad.
🎯 The Strategic Outlook: Competitive Moats, Risks & Future Growth Plans
Competitive Advantages & Economic Moats
Virinchi Limited maintains specialized operational barriers across its technology and clinical ecosystems:
- Alternative Lending Domain Specialization: QFund integrates two decades of statutory compliance rules across diverse U.S. state lending jurisdictions, embedding complex payroll deduction, consumer lending limits, and underwriting configurations that make platform switching costly for alternative finance institutions.
- Integrated Healthcare IT & Clinical Workflows: Ownership of the proprietary vHealth and Asclepius HIMS software platforms enables digitized bedside documentation, automated electronic health record generation, and centralized management dashboards, reducing administrative overhead relative to peer hospitals.
- Competitive Capital Efficiency: Hospital infrastructure was established at a capital cost of approximately ₹0.45 Crores per operational bed, well below prevailing industry benchmarks of ₹0.60 Crores per bed for tertiary multi-specialty setups.
What Could Go Wrong? Key Challenges & Business Risks
The enterprise faces structural and operating headwinds across its primary divisions:
- Geographic Concentration: 68.33% of operating revenues are tied to the North American marketplace, exposing foreign exchange earnings to changes in U.S. non-bank lending regulations and Federal interest rate cycles.
- Immigration & Visa Policy Vulnerabilities: IDC & IT Services performance declined significantly due to restrictions on U.S. H-1B visa issuances, constraining cross-border resource deployments and prompting a transition toward local U.S. hiring.
- High Financial Leverage & Lease Liabilities: Sustained lease financing liabilities of ₹132.06 Crores under Ind AS 116 for the Banjara Hills facility create fixed annual finance expenses (₹17.83 Crores in FY 2025-26) that weigh on consolidated operating margins.
- Statutory Dues Delays: Independent statutory auditors highlighted delays in depositing undisputed statutory dues under Clause 3(vii) of CARO 2020, resulting from temporary cash-flow mismatches and extended working capital collections.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Management has outlined three targeted strategic execution priorities through FY 2028:
- Multi-Tenant SaaS Rollout: Transitioning QFund into a flexible, multi-tenant cloud delivery architecture to capture mid-sized and regional non-banking lending store networks without bespoke deployment cycles.
- Oncology & Mother/Child Expansion: Completion and commissioning of the dedicated radiation oncology block and mother & child care wing at Banjara Hills by April 2028. This addition will round out the hospital’s comprehensive oncology care suite and generate cross-departmental consultations.
- Hospital Slump Sale Reorganisation: Integration of the Barkatpura and Hayathnagar secondary hospital branches under Virinchi Limited’s direct corporate balance sheet following postal ballot approval on August 12, 2026, for ₹100.00 Crores, optimizing the operational cost structure.
The Verdict: Strategic Outlook & Conclusion
Virinchi Limited represents a differentiated hybrid of high-margin export fintech intellectual property and asset-backed domestic healthcare delivery. The primary financial challenge remains addressing the drag that healthcare lease costs place on consolidated net profits, even as pure SaaS standalone margins demonstrate underlying operational health.
The successful conversion of promoter equity warrants, reduction in debt gearing to 0.29x, ongoing balance sheet restructuring via slump sale acquisitions, and planned commercialization of the oncology wing by 2028 position the enterprise to transition from restructuring toward steady operational scale.
Frequently Asked Questions (FAQs) About Virinchi Limited
Q1: What are the core business operations and flagship brands of Virinchi Limited?
Virinchi Limited operates across three main sectors: Fintech SaaS (anchored by its flagship U.S. alternative lending platform, QFund), IDC & IT Services (managed by U.S. subsidiary KSoft Systems Inc.), and Tertiary Healthcare Delivery (anchored by Virinchi Hospitals, a 400-bed multi-specialty facility at Banjara Hills, Hyderabad).
Q2: What was the financial performance of Virinchi Limited in FY 2025-26?
In FY 2025-26, Virinchi Limited recorded consolidated revenue from operations of ₹284.36 Crores and total income of ₹286.13 Crores. Operating EBITDA stood at ₹0.71 Crores, but consolidated operations recorded a net loss of ₹26.12 Crores due to bad-debt write-offs of ₹8.43 Crores, ₹5.30 Crores in prior-period tax adjustments, and ₹17.83 Crores in lease finance charges. Standalone operations remained profitable with a PAT of ₹13.98 Crores.
Q3: Who founded Virinchi Limited, and what is the current shareholding structure?
The company was founded in 1990 by First Generation IIT/IIM entrepreneurs led by Viswanath Kompella (Founder & Chairman Emeritus). As of March 31, 2026, the promoter group holds a 40.10% equity stake, while the public and non-institutional shareholders hold 59.90%. Key individual promoter Viswanath Kompella holds 15.05% directly.
Q4: Where are Virinchi Limited’s software centers and healthcare facilities located?
Software development hubs are located in Banjara Hills and Hakimpet (Hyderabad), supported by an onshore center in Marlboro, New Jersey, and co-located internet data centres in Atlanta and Santa Clara, USA. Healthcare infrastructure comprises three hospital centers in Hyderabad: Banjara Hills (flagship 400 beds), Barkatpura, and Hayathnagar.
Q5: What is the debt and net worth position of Virinchi Limited?
As of March 31, 2026, Virinchi Limited reported a consolidated net worth (total equity) of ₹482.16 Crores. Total consolidated debt stood at ₹141.32 Crores (down from ₹159.99 Crores), resulting in an improved debt-to-equity ratio of 0.29x and an interest coverage ratio of 2.17x.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.virinchi.com